NewAmsterdam Pharma NAMS Q1 2026 Earnings EPS Beat Reflects Cost Management Amid PreRevenue Phase EXAS Q4 2025 Earnings Significant EPS Miss Raises Questions on Path to Profitability Skye Bioscience Q1 2026 Earnings WiderthanExpected Loss Highlights PreRevenue Biotech Challenges SFBS Q1 2026 Earnings EPS Slightly Beats Estimates Stock Declines Marginally Avita Medical Q1 2026 Earnings EPS Misses Estimates as Strategic Investments Continue VMD Q1 2026 Earnings EPS Misses Estimates but Positive Stock Response Signals Underlying Confidence